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Systemic lupus erythematosusNeuropsychiatric systemic lupus erythematosus (NPSLE) is one of themost difﬁcult manifestations of lupus to
diagnose. Measurement of serum brain antibodies has contributed to early diagnosis and management of
NPSLE before development of a debilitating disease.We aimed to assess the value of serumanti-gangliosideM1
antibodies in prediction of NPSLE, in comparison to other antibodies used in routine laboratory diagnosis of
NPSLE. In addition,we are the ﬁrst to study the relationship between these antibodies and cognitive function in
lupus patients. Serum anti-ganglioside M1, anti-ribosomal P protein and anti-cardiolipin antibodies were
measured in 30 lupus patients without clinical evidence of NPSLE, aged 8–16 years, and 30 healthy matched-
subjects. Patients were followed-up clinically by monthly neuropsychiatric evaluation and assessment of
cognitive function for 12 months. Twelve patients developed neuropsychiatric manifestations during follow-
up. Of those patients, 83.3%, 50% and 16.7% were seropositive for anti-ganglioside M1, anti-ribosomal P and
anti-cardiolipin antibodies, respectively at the time of initial evaluation before clinical presentation of NPSLE.
There was a signiﬁcant positive association between anti-ganglioside seropositivity and cognitive dysfunction
(Pb0.001). In addition, anti-ganglioside seropositivity had a signiﬁcant risk for association with cognitive
dysfunction (odds ratio: 36; 95% CI: 4.3–302.8). Conclusions: Serum anti-ganglioside M1 antibodies had a
higher predictive value for NPSLE than other antibodies used in routine laboratory diagnosis of this disease.
Thus, they may be reliable parameters for early diagnosis and management of NPSLE before clinical
manifestations ensue. In addition, anti-ganglioside M1 antibodies may play a role in cognitive dysfunction
found in some lupus patients.off Makram Ebaid, Nasr City,
x: +20 2 4820237.
tafa@hotmail.com
-NC-ND license. © 2010 Elsevier B.V. Open access under CC BY-NC-ND license. 1. Introduction
Involvement of the nervous system in systemic lupus erythema-
tosus (SLE) encompasses a wide variety of neurologic and psychiatric
manifestations. These manifestations vary widely from life threaten-
ing presentation, such as transverse myelitis or stroke to subtle and
subclinical abnormalities in neurocognitive function such as memory,
intellect and learning (Sanna et al., 2003). Neuropsychiatric systemic
lupus erythematosus (NPSLE) includes the neurologic syndromes of
the central, peripheral and autonomic nervous systems and the
psychiatric syndromes observed in patients with SLE in which other
causes have been excluded (Nived et al., 2003).
The American College of Rheumatology ACR Ad Hoc Committee on
Neuropsychiatric Lupus Nomenclature (1999) has produced a
standard nomenclature and a set of 19 case deﬁnitions for NPSLE
(Sibbitt et al., 2002; Hanly et al., 2004). The commonest manifesta-tions of NPSLE include cognitive dysfunction, acute confusional states,
anxiety disorder, mood disorder and psychosis (Stojanovich et al.,
2007). Cognitive dysfunction (memory, attention, language, concept
formation, problem solving, executive and visuospatial dysfunctions)
is one of the most frequent manifestations of NPSLE resulting in a
signiﬁcant impact on their ability to function (Sibbitt et al., 2002). It
reﬂects an immune-mediated compromise of the underlying neuronal
substrate rather than the non-speciﬁc effects of chronic illnesses or its
treatment (Carbotte et al., 1995; Khedr et al., 2001). NPSLEmay be the
ﬁrst indications of SLE and can be present when SLE disease activity
cannot be detected in other organ systems (Kajs-Wyllie, 2002; Hanly
et al., 2009). CNS involvement indicates an increased risk for nervous
system damage and premature death and it ranks second to renal
failure as a cause of death in SLE (Karassa et al., 2000).
It is paramount in the diagnosis of any patient with NPSLE that
secondary causes (e.g. infection, electrolyte imbalance, hypertension,
uraemia and medications) are excluded and treated appropriately as
they are twice as common as primary NPSLE (Teh, 2003). The accurate
diagnosis of primary NPSLE and its differentiation from secondary
central nervous system involvement are challenging (Yoshida et al.,
2007). NPSLE is one of the most difﬁcult manifestations of lupus to
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(Teh, 2003). The major advances in laboratory and neuroimaging
studies may contribute to an earlier and a more speciﬁc diagnosis of
nervous involvement in SLE for a better clinical care before the
development of a debilitating disease (Kajs-Wyllie, 2002; Castellino
et al., 2008; Efthimiou and Blanco, 2009). In addition, testing for brain
antibodies may help in distinguishing between primary and second-
ary NPSLE (Tzioufas et al., 2000).
Testing for anti-ribosomal P and anti-phospholipid antibodies,
which have been associated with some neurological manifestations of
SLE, are currently routinely available in most diagnostic laboratories.
However, inconsistencies in their prevalence and clinical correlations
have become an obstacle to their use as diagnostic markers of the
disease (Tzioufas et al., 2000; Greenwood et al., 2002).
Gangliosides are a family of sialylated glycosphingolipids
expressed in the outer leaﬂet of the plasma membrane of the cells
of all vertebrates. They are particularly abundant in the nervous
system, in particular at synapses and they are, to some extent,
involved in neurotransmission at the neuromuscular junction (Ariga
et al., 2008; Zitman et al., 2008, 2009, 2010). Gangliosides are thought
to play important roles inmemory formation, neuritogenesis, synaptic
transmission, and other neural functions (Kato and Hatanaka, 2008;
Sugiura et al., 2008). The administration of exogenous gangliosides
seems to improve nerve regeneration (Ribeiro et al., 2008). Gangli-
oside M1 is the most abundant ganglioside in neural membranes. It
may be an autoantigen through the galactose–galactosamine part of
its sugar moiety (Plomp and Willison, 2009). In humans, gangliosides
elicit a T-cell independent IgM response (Ravindranath et al., 2005).
In immune-mediated neurological disorders, various antibodies
against neuronal tissues have been discovered. Some of these
antibodies have been found to correlate with the pathomechanism
of the disease (Watanabe and Arimura, 2008). The key to establish an
immunopathogenic role for a brain autoantibody is to determine its
effects on speciﬁc brain functions (Greenwood et al., 2002).
With this background, we aimed to assess the value of serum anti-
ganglioside M1 antibodies in the prediction of NPSLE, in comparison
to antibodies used in routine laboratory diagnosis of NPSLE. The
relationship between these antibodies and cognitive functionwas also
studied.
2. Materials and methods
2.1. Study population
This case–control, follow-up study was conducted over a period of
15 months from the beginning of September 2008 to the end of
November 2009. It included 30 patients (24 females and 6males) with
SLE diagnosed according to the American Rheumatism Association
Revised Criteria for diagnosis of SLE (Hochberg, 1997). Patients were
recruited from the Pediatric Allergy and Immunology Unit, Children's
Hospital, Ain Shams University, Cairo, Egypt. Their ages ranged
between 8 and 16 years with a mean age of 11.6±2.7 years. All
lupus patients had no NPSLE according to the absence of clinical
evidence of nervous system involvement, based on the 19 standard
neuropsychiatric syndromes in SLE deﬁned by the ACR Ad Hoc
Committee on Neuropsychiatric Lupus Nomenclature (1999). Patients
with cognitive dysfunction or neuropsychiatric manifestations were
excluded from the study.
In addition, all lupus patients were receiving oral prednisolone
(0.5–2 mg/kg/day) either alone (n=24) or in combination with other
immunosuppressive drugs such as intravenous pulse cyclophospha-
mide (n=6). Patients were followed-up clinically by monthly
neuropsychiatric examination and assessment of cognitive function
for 12 months.
Patients were studied in comparison to 30 age- and sex-matched
apparently healthy children recruited from the Outpatients Clinic,Children's Hospital, Ain Shams University, serving as controls. They
were the sibs of the children attending this clinic because of a minor
illness (e.g. common cold, tonsillitis, acute bronchitis, … etc). The
control children had no clinical ﬁndings suggesting immune or
neuropsychiatric disorders. They were 24 females and 6 males.
Their ages ranged between 8 and 16 years with a mean age of 11.5±
2.4 years.
An informed written consent was signed by the parents or the
caregivers of each studied subject before enrollment in the study.
2.2. Study measurements
2.2.1. Clinical evaluation of lupus patients
This was based on clinical history taking from caregivers,
reviewing follow-up sheets and clinical examination. Special empha-
sis was done on assessment of disease activity, by using systemic
lupus erythematosus disease activity index “SLEDAI” (Bombardier
et al., 1992), neurological manifestations (e.g. convulsions, motor or
sensory changes, transient ischemic attacks “TIATs”, involuntary
movements, headache, … etc) and psychiatric examination using
minikid schedule (Sheehan et al., 1998).
2.2.2. Assessment of cognitive function
Cognitive function (memory, attention, language, concept forma-
tion, problem solving, executive and visuospatial functions) was
assessed with age-appropriate, translated and validated psychometric
instruments that were administered by well-trained psychologists
using a set of Arabic norms (Meleka and Ismail, 1999) for a translated
Wechsler Intelligence Scale for Children, 3rd edition “WISC-III”
(Wechsler, 1991). This scale is the most commonly used test to
assess cognitive function in the children. Three global measures were
examined in the present study. The verbal intelligence quotient (IQ) is
derived from different subtests including information, similarities,
arithmetic, comprehension, vocabulary and digit span. The perfor-
mance IQ is derived from different subtests including picture
completion, block design, picture arrangement, object assembly and
digit symbol. The full-scale IQ is the sum of the verbal and
performance IQ. The individual subtests may be particularly useful
because each depends on a variety of capabilities and dysfunction of
any one could result in a low score on one of the global measures.
Cognitive dysfunction is diagnosed when the difference between
verbal and performance IQ is more than 15 and/or the result of one or
more of the individual subtests is below 7 and/or the full-scale IQ is
below 70.
2.2.3. Measurement of serum anti-ganglioside M1 IgM and IgG
antibodies
Measurement of serum anti-ganglioside M1 IgM and IgG antibodies
wasdonebyELISA for determining the levels of anti-gangliosideM1 IgM
and IgG antibodies in biological samples (Buhlmann Laboratories AG,
Baselstrasse 55, CH-4124 Schonenbuch, Switzerland). Brieﬂy, anti-
ganglioside M1 antibodies from patients' sera, calibrators and controls
were incubated with ganglioside M1 coated onto microtitre wells.
After the removal of unreacted material by a washing step, horseradish
peroxidase-labeled antibodies against human IgM and IgG were added
to wells. After the second washing step, the enzyme substrate tetra-
methylbenzidin was added to the wells. Blue color developed in
proportion to the amount of anti-gangliosideM1 IgMand IgGantibodies
bound in the initial step. The reactionwas terminated by the addition of
stop solution and the color turned from blue to yellow. The absorbance
was measured in a microtitre plate reader at a wave length of 450 nm.
Resultswere calculated byusing a standard curvewhere the absorbance
of calibrators was plotted versus their corresponding titre units on a lin/
log graphpaper. The lowerdetection limits for anti-gangliosideGM1 IgG
and IgM isotypes are 59 BTU and 52 BTU, respectively (Morton, 2005).
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antibodies
Serum total IgG and IgM anti-ribosomal P protein antibodies were
measured by ELISA using ribosomal P peptide-bovine serum albumin
conjugate as an antigen (Nunc immuno module F8 maxisorp; Nunc.
Roskilde, Denmark). The lower detection limit for anti-ribosomal P
protein antibodies is 1.0 U/dl (Yoshio et al., 1995).
2.2.5. Routine laboratory investigations of SLE
Routine laboratory investigations of SLE include complete blood
picture, ﬁrst hour erythrocyte sedimentation rate (Westergren
method), routine microscopic urine analysis, 24 hour urine protein,
serum and urinary creatinine, corrected creatinine clearance, serum
complement 3, ANA (immuno-ﬂuorescence technique), anti ds-DNA
(ELISA) and anti-cardiolipin antibodies (ELISA).
2.3. Statistical analysis
The results were analyzed by commercially available software
package (Statview, Abacus concepts, inc., Berkley, CA, USA). The data
were non-parametric, thus they were presented as median and
interquartile range (IQR), which is the difference between the 25th
and 75th percentiles. Mann–Whitney test was used for comparison
between non-parametric data. Spearman's correlation coefﬁcient “r”
was used to determine the relationship between different quantita-
tive variables. Chi-square (χ2) test was used for comparison between
qualitative variables of the studied groups. A probability (P) of less
than 0.05 was considered signiﬁcant. Risk estimation was done to
calculate the odds ratio and its 95% conﬁdence interval (CI). CI is
signiﬁcant when the value of 1 is not included in its range. Patients
were considered to be seropositive for either anti-ganglioside M1 IgM
or IgG antibodies if the levels of these antibodies were above the
calculated highest cut-off value (the 95th percentile of the control
values, which was 800 Buhlmann titre unit (BTU) for both
antibodies).
3. Results
The characteristics of the study subjects are shown in Table 1.
During follow-up, 12 patients developed clinical evidence of
NPSLE. Out of those patients, 2 had cognitive dysfunction and 2 had
neuropsychiatric manifestations (focal convulsions, severe depression
and moderate anxiety in one patient and TIATs, moderate depression
and signs of pyramidal tract lesion in the other patient). The
remaining 8 patients had both clinical evidence of cognitive
dysfunction and neuropsychiatric manifestations (signs of pyramidalTable 1
Basic clinical data of lupus patients and healthy controls.
Clinical data Lupus patients
(n=30)
Control group
(n=30)
Age (year) Range: 8–16 Range: 8–16
Mean±SD: 11.6±2.7 Mean±SD: 11.5±2.4
Sex (F/M) 24/6 24/6
Duration of illness (year) Range: 1–4
Median (IQR): 2 (1.3)
SLEDAI Range: (10–70)
Median (IQR): 25 (25)
Clinical evidence of NPSLE 12/30 (40%)
Cognitive dysfunction 2/12
NP manifestations 2/12
Cognitive dysfunction
and NP manifestations
8/12
IQR, interquartile range. NP, neuropsychiatric manifestations. NPSLE, neuropsychiatric
systemic lupus erythematosus. SLEDAI, systemic lupus erythematosus disease activity
index.tract lesion in 2 patients, TIATs and moderate depression in another 2
patients, sensory changes suggestive of peripheral neuritis and severe
depression in another patient, lower motor cranial nerve lesions
localized to brain stem and severe depression in one patient, signs of
pyramidal tract lesionwith severe anxiety in another patient and focal
convulsions, moderate depression and lower motor cranial nerve
lesions localized to brain stem in the remaining patient).3.1. Serum anti-ganglioside M1 antibodies in lupus patients and healthy
controls
Lupus patients had signiﬁcantly higher serum anti-ganglioside M1
IgM antibodies than healthy controls (Pb0.001). In contrast, lupus
patients and healthy controls had comparable values of serum anti-
ganglioside M1 IgG antibodies (P=0.4) (Table 2).
Seropositivity of anti-ganglioside M1 IgM antibodies was found in
33.3% (10/30) of lupus patients, while seropositivity of anti-
ganglioside M1 IgG antibodies was found in 13.3% (4/30) of those
patients. In addition, 13.3% (4/30) of lupus patients were seropositive
for both anti-ganglioside M1 isotypes (IgM and IgG).
On the other hand, patients who developed clinical evidence of
NPSLE during follow-up (n=12) had signiﬁcantly higher serum anti-
ganglioside M1 IgM antibodies than patients without such evidence
(n=18), Pb0.001. In contrast, patients with and without NPSLE had
comparable values of serum anti-ganglioside M1 IgG antibodies
(P=0.1) (Table 2).3.2. Serum anti-ribosomal P and anti-cardiolipin antibodies in lupus
patients and healthy controls
Lupus patients had signiﬁcantly higher serum anti-ribosomal P
and anti-cardiolipin IgM antibodies than healthy controls (Pb0.001
and Pb0.001, respectively). In contrast, lupus patients and healthy
controls had comparable values of serum anti-cardiolipin IgG
antibodies (P=0.5) (Table 3).
Seropositivity of anti-ribosomal P antibodies was found in 20% (6/
30) of lupus patients. In addition, 16.7% (5/30) and 13.3% (4/30) of
those patients were seropositive for anti-cardiolipin IgM and IgG
antibodies, respectively. Moreover, 6.67% (2/30) of lupus patients
were seropositive for both anti-cardiolipin isotypes (IgM and IgG).
On the other hand, patients with clinical evidence of NPSLE had
signiﬁcantly higher serum anti-ribosomal P antibodies than patients
without such evidence, Pb0.001. In contrast, patients with and
without NPSLE had comparable values of serum anti-cardiolipin IgM
and IgG antibodies (P=0.4 and P=0.1, respectively) (Table 3).Table 2
Serum concentrations of anti-ganglioside M1 antibodies in lupus patients and healthy
controls.
Study subjects Anti-ganglioside M1 Anti-ganglioside M1
IgM antibodies (BTU) IgG antibodies (BTU)
Range Median (IQR) Range Median (IQR)
Healthy controls (n=30) 200–800 390 (505) 240–800 680 (450)
All lupus patients (n=30) 380–4300 710 (2215) 260–2800 640 (225)
Patients with NPSLE
(n=12)
650–4300 3200 (1900) 480–2800 690 (958)
Patients without NPSLE
(n=18)
380–780 650 (135) 260–780 635 (225)
Z1 (P) 4 (b0.001) 0.9 (0.4)
Z2 (P) 4.2 (b0.001) 1.6 (0.1)
BTU, Buhlmann titre unit. IQR, interquartile range. NPSLE, neuropsychiatric systemic
lupus erythematosus. Z1, comparison between all lupus patients and controls. Z2,
comparison between patients with and those without NPSLE.
Table 3
Serum concentrations of total (IgM+IgG) anti-ribosomal P protein and both IgM and
IgG anti-cardiolipin antibodies in lupus patients and healthy controls.
Study subjects Total anti-ribosomal
P antibodies
Anti-cardiolipin
IgM antibodies
Anti-cardiolipin
IgG antibodies
(Units/dl) (MPL) (GPL)
Median (IQR) Median (IQR) Median (IQR)
Healthy controls
(n=30)
8.5 (6.1) 2 (1.6) 4.5 (1)
All lupus patients
(n=30)
14 (5) 4 (0.6) 4 (1)
Patients with NPSLE
(n=12)
19 (25.8) 4 (7.6) 4 (0.9)
Patients without
NPSLE (n=18)
13 (4) 4 (0.5) 4 (1.3)
Z1 (P) 4.3 (b0.001) 4.4 (b0.001) 0.6 (0.5)
Z2 (P) 4.5 (b0.001) 0.8 (0.4) 1.6 (0.1)
BTU, Buhlmann titre unit. IQR, interquartile range. NPSLE, neuropsychiatric systemic
lupus erythematosus. Z1, comparison between all lupus patients and controls. Z2,
comparison between patients with and those without NPSLE.
Table 4
Percentage of lupus patients with positive results of the studied serum antibodies.
Seropositivity for the studied serum
antibodies
Patients with
clinical evidence
of NPSLE
Patients without
clinical evidence
of NPSLE
Seropositivity for anti-ganglioside M1
IgM antibodies (n=10)
10/12 (83.3%) 0/18
Seropositivity for anti-ribosomal P
antibodies (n=6)
6/12 (50%) 0/18
Seropositivity for anti-cardiolipin IgM
antibodies (n=5)
2/12 (16.7%) 3/18 (16.7%)
Seropositivity for both anti-ganglioside
M1 IgM and anti-ribosomal P antibodies
(n=4)
4/12 (33.3%) 0
Seropositivity for both anti-ganglioside
M1 IgM and anti-cardiolipin IgM
antibodies (n=2)
2/12 (16.7%) 0
Seropositivity for both anti-ribosomal P and
anti-cardiolipin IgM antibodies (n=2)
2/12 (16.7%) 0
NPSLE, neuropsychiatric systemic lupus erythematosus.
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At the time of initial evaluation, before the clinical presentation of
NPSLE, seropositivity of anti-ganglioside M1, anti-ribosomal P and
anti-cardiolipin antibodies was found in 83.3%, 50% and 16.7%,
respectively of patients who developed clinical evidence of NPSLE,
later on, during follow-up. Seropositivity for both anti-ganglioside M1Table 5
Clinical evidence of cognitive dysfunction and the time of its diagnosis in the 10 lupus pati
Lupus patients with
cognitive dysfunction
Clinical evidence of cognitive dysfunction and the
Deﬁcits in the subsets of verbal IQ
1 The difference between verbal and performance I
2 Arithmetic (after 2 months)
3 Arithmetic (after 2 months)
Digit span (after 5 months)
4 Arithmetic (after 3 months)
Digit span (after 4 months)
5
6
7 Arithmetic (after 3 months)
8 Digit span (after 5 months)
9 Arithmetic (after 2 months)
Digit span (after 6 months)
10 Arithmetic (after 4 months)
Digit span (after 7 months)and anti-ribosomal P antibodies was detected in 33.3% of those
patients (Table 4). Interestingly, all patients who developed clinical
evidence of NPSLE, during follow-up, were seropositive for at least
one of the studied antibodies.
In contrast, none of the 18 patients who had no clinical evidence of
NPSLE was seropositive for either anti-ganglioside M1 or anti-
ribosomal P antibodies. On the other hand, 16.7% of those patients
were seropositive for anti-cardiolipin antibodies (Table 4).3.4. Cognitive function in lupus patients and healthy controls
Clinical evidence of cognitive dysfunctionwas detected in 10 lupus
patients (33.3%) during follow-up. Thus, 83.3% (10/12) of lupus
patients with clinical evidence of NPSLE had cognitive dysfunction.
The difference between verbal and performance IQ was more than
15 in one patient. Another 3 patients had deﬁcits in one or more of the
subsets of verbal IQ (arithmetic in one and arithmetic and digit span in
the remaining 2 patients). Two more patients had deﬁcits in one or
more of the subsets of performance IQ (block design in one patient
and both block design and digit symbol in the remaining patient).
Another 2 patients had deﬁcits in one or more of the subsets of both
verbal and performance IQ (arithmetic and digit symbol in one patient
and digit span and block design in the remaining patient). The
remaining 2 patients had full-scale IQ below 70 and deﬁcits in one or
more of the subsets of verbal and/or performance IQ (arithmetic, digit
span and digit symbol in one patient and arithmetic, digit span and
block design in the remaining patient) (Table 5). Thus, deﬁcits in
arithmetic, digit span, block design and digit symbol subsets of verbal
and performance IQwere found in 6, 5, 4 and 3 childrenwith cognitive
dysfunction, respectively.
Clinical evidence of cognitive dysfunction was found in only 6.7%
(2/30) of healthy children. One child had deﬁcits in arithmetic and
digit span and the other one had deﬁcits in arithmetic and block
design. The frequency of cognitive dysfunction was signiﬁcantly
higher in lupus patients than healthy children, Pb0.001.3.5. Association between cognitive dysfunction and the studied serum
antibodies in lupus patients
There was a signiﬁcant positive association between anti-gangli-
oside M1 seropositivity and cognitive dysfunction as the frequency of
anti-ganglioside M1 seropositivity was signiﬁcantly higher in patients
with cognitive dysfunction than patients with normal cognitive
function (Pb0.001). In addition, anti-ganglioside seropositivity had
a signiﬁcant risk for association with cognitive dysfunction (odds
ratio: 36; 95% CI: 4.3–302.8) (Table 6).ents during the 12 month follow-up.
time of their diagnosis during the 12 month follow-up
Deﬁcits in the subsets of performance IQ Full-scale IQ below 70
Q was more than 15 (after 6 months)
Block design (after one month)
Block design (after 2 months)
Digit symbol (after 9 months)
Digit symbol (after 4 months)
Block design (after 3 months)
Digit symbol (after 8 months) After 9 months
Block design (after 4 months) After 11 months
Table 6
Association between seropositivity of the studied antibodies and cognitive dysfunction.
Cognitive
dysfunction
Normal cognitive
function
χ2 Odds ratio
(n=10) (n=20) (P) (95% CI)
Anti-ganglioside
M1 positive
8 (80%) 2 (10%) 14.7 36
Anti-ganglioside
M1 negative
2 (20%) 18 (90%) (b0001) 4.3–302.8
Anti-ribosomal P positive 4 (40%) 2 (10%) 3.75 6
Anti-ribosomal P negative 6 (60%) 18 (90%) (0.053) 0.87–41.4
Anti-cardiolipin positive 1 (10%) 4 (20%) 0.48 0.4
Anti-cardiolipin negative 9 (90%) 16 (80%) (0.48) 0.04–4.6
Table 7
SLEDAI scores of lupus patients in relation to clinical evidence of NPSLE and
seropositivity of the studied serum antibodies.
SLEDAI scores z p
Median (IQR)
Clinical evidence of NPSLE 20 (25) 1.3 0.2
No clinical evidence of NPSLE 31 (26)
Anti-ganglioside M1 positive 20 (29) 0.4 0.7
Anti-ganglioside M1 negative 31 (25)
Anti-ribosomal P positive 30 (21) 0.4 0.7
Anti-ribosomal P negative 22 (28)
Anti-cardiolipin positive 30 (45) 0.5 0.6
Anti-cardiolipin negative 25 (25)
NPSLE, neuropsychiatric systemic lupus erythematosus. SLEDAI, systemic lupus
erythematosus disease activity index.
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signiﬁcantly higher in patients with cognitive dysfunction than
patients with normal cognitive function, this difference did not
reach statistical signiﬁcance (P=0.053). On the other hand, there was
a non-signiﬁcant difference between the frequency of anti-cardiolipin
seropositivity of patients with and without cognitive dysfunction
(P=0.48) (Table 6).
3.6. Association between disease activity, as assessed by SLEDAI, and
both clinical evidence of NPSLE and seropositivity of the studied serum
antibodies in lupus patients
There was a non-signiﬁcant statistical difference between SLEDAI
of patients with and without clinical evidence of NPSLE (P=0.2) and
seropositivity of anti-ganglioside M1, anti-ribosomal P and anti-
cardiolipin antibodies (P=0.7, P=0.7 and P=0.6, respectively)
(Table 7). In addition, serum anti-ganglioside M1 IgG and IgM, anti-
ribosomal P and anti-cardiolipin IgG and IgM antibodies did not
correlate signiﬁcantly to SLEDAI of lupus patients (P=0.7, P=0.6,
P=0.9, P=0.2 and P=0.4, respectively).Table 8
Association between seropositivity of ANA and anti ds-DNA and both clinical evidence of N
ANA positive ANA negative χ
(n=25) (n=5) (
Clinical evidence of NPSLE 11 (44%) 1 (20%) 1
No clinical evidence of NPSLE 14 (56%) 4 (80%) (
Anti-ganglioside M1 positive 9 (36%) 3 1
Anti-ganglioside M1 negative 16 (64%) 2 (
Anti-ribosomal positive 4 (16%) 2 (40%) 1
Anti-ribosomal P negative 21(84%) 3 (60%) (
Anti-cardiolipin positive 4 (16%) 1 (20%) 0
Anti-cardiolipin negative 21 (84%) 4 (80%) (
ANA, antinuclear antibodies. Anti ds-DNA, anti-double stranded DNA. NPSLE, neuropsychia3.7. Association between seropositivity of both ANA and anti ds-DNA and
both clinical evidence of NPSLE and seropositivity of the studied serum
antibodies in lupus patients
There were non-signiﬁcant associations between seropositivity of
both ANA and anti ds-DNA and clinical evidence of NPSLE (P=0.3 and
P=0.4, respectively). Similarly, ANA and anti ds-DNA had no
signiﬁcant associations with seropositivity of anti-ganglioside M1
(P=0.3 and P=0.4, respectively), anti-ribosomal P (P=0.2 and
P=0.7, respectively) and anti-cardiolipin antibodies (P=0.8 and
P=0.7, respectively) (Table 8).
4. Discussion
The diagnosis of NPSLE is based on the combination of clinical
features and immunoserological tests (Hermosillo-Romo and Brey,
2002). In the current study, the frequency of NPSLE was 40%. Previous
estimates of the prevalence of NPSLE ranged from 17 to 75% reﬂecting
variable diagnostic criteria and heterogeneity in the clinical popula-
tions studied (Colasanti et al., 2009).
The pathogenic mechanisms involved in primary NPSLE are
obscure. Proposed mechanisms include antibody-mediated neuronal
cell injury or dysfunction and vascular occlusion due to vasculopathy,
vasculitis, leukoaggregation or thrombosis (Sany-Choel, 2003). The
development of organ-associated autoantibodies generally precedes
the appearance of their associated clinical features in lupus patients
(Heinlen et al., 2007). Distinct antibodies detectable in serum of lupus
patients are associated with the presence of neuropsychiatric
disorders. These antibodies may have a pathogenic relevance in
NPSLE or they may be merely an epiphenomenon (Colasanti et al.,
2009).
Indeed, due to their location in the nervous system, gangliosides
could be a target molecule in the complex autoimmune response and
thus, may play a pathogenic role in NPSLE (Galaezzi et al., 2000). In
the present study, lupus patients had signiﬁcantly higher serum anti-
ganglioside M1 IgM antibodies than healthy controls (Pb0.001). The
current study also revealed seropositivity of anti-ganglioside M1
antibodies in 33.3% (10/30) of lupus patients. Studies regarding serum
anti-ganglioside M1 IgM antibodies in SLE are very few. A previous
study reported anti-gangliosideM1 seropositivity in 10 out of 60 adult
patients with SLE (16.6%) and the incidence of these antibodies was
not signiﬁcantly higher in lupus patients with symptoms related to
the nervous system than in patients without neurological involve-
ment (Martinez et al., 1992). Another study conducted on 448 with
SLE enrolled in 8 centers from 6 European countries reported
seropositivity of anti-ganglioside M1 antibodies in 15.5% of the
studied patients and both anti-ganglioside M1 isotypes were
associated with neuropsychiatric manifestations (Galaezzi et al.,
2000). The discrepancies between the results of these studies may
be attributable to the variations in the number of the studied lupus
patients, their ages and the frequency of the neuropsychiatric
manifestations in these patients. As the number of the studiedPSLE and seropositivity of the studied serum antibodies.
2 Anti ds-DNA positive Anti ds-DNA negative χ2
P) (n=20) (n=10) (P)
9 (45%) 3 (30%) 0.6
0.3) 11 (55%) 7 (70%) (0.4)
7 (35%) 5 (50%) 0.5
0.3) 13 (65%) 5 (50%) (0.4)
.5 5 (25%) 1 (10%) 0.09
0.2) 15 (75%) 9 (90%) (0.7)
.04 3(45%) 2 (20%) 0.1
0.8) 17(45%) 8 (80%) (0.7)
tric systemic lupus erythematosus.
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investigate the frequency of anti-ganglioside M1 antibodies in
Egyptian pediatric lupus patients and to study their relations to
neuropsychiatric ﬁndings is recommended.
The reason behind this seropositivity is not fully understood. It is
speculated that this autoimmune reaction to neuronsmight be trigged
by other cross-reacting antigens in the environment resulting in the
release of neuronal antigens which through the activation of
inﬂammatory cells, may result in autoimmune reactions in genetically
susceptible individuals. The following chain of events may lead to the
production of brain antibodies. First: pre-existing autoreactive T-cells
are generated bymolecular mimicry as a result of contact with dietary
proteins or infectious agents antigens, with sequence homologies
with autoantigens. Second: toxic chemicals (such as bacterial
enterotoxins, and heavy metals), may increase adhesion molecules
on brain endothelial cells. Third: pre-existing autoreactive T-cells may
transmigrate across the blood–brain barrier (BBB) and induce
activation of local antigen-presenting cells (such as microglia and
astrocytes). Lastly: production of cytokines by T-helper-1 autoreactive
antigen-presenting cells may result in oligodendrocyte damage and
demyelination. These events result in the release of antigens from
neuroﬁlaments that enter the circulation producing immune reac-
tions due to the formation of plasma cells which produce antibodies
against neuron-speciﬁc antigens. These antibodies may cross the BBB
and combine with brain tissue antigens forming immune complexes,
thus further damaging the neurological tissue (Vojdani et al., 2002).
Tests for anti-ganglioside antibodies remain highly specialized,
whereas tests for ribosomal P antibodies and for anti-phospholipid
antibodies are currently routinely available in most diagnostic
laboratories (Greenwood et al., 2002). In the current study, lupus
patients had signiﬁcantly higher serum anti-ribosomal P antibodies
than healthy controls (Pb0.001). Seropositivity of anti-ribosomal P
antibodies was found in 20% (6/30) of our lupus patients. Other
investigators reported positivity of anti-ribosomal P antibodies in
21.9% (7/32) of lupus patients, all of whom had one or more NPSLE
syndromes. These investigators also reported that anti-ribosomal P
antibodies were speciﬁc, but not sensitive, for NPSLE (Abdel-Nasser
et al., 2008). The association of anti-ribosomal P antibodies with
psychiatric or neurological manifestations has been proposed, but
remains controversial (Caponi et al., 2007).
Antibodies have long been suspected to play a central role in the
pathogenesis of NPSLE (Greenwood et al., 2002). This argument was
supported by our ﬁnding of a signiﬁcant increase of serum levels of
anti-ganglioside M1 IgM and anti-ribosomal P antibodies in patients
with (n=12) than those without NPSLE (n=18) (Pb0.001). These
results may indicate the possible pathogenic role of these antibodies
in nervous involvement in SLE. However, it is far from clear whether
autoimmunity to neuronal antigens is a consequence of the disease or
actually initiates the process (Plomp and Willison, 2009).
In the presentwork, of the 12 patients who developed NPSLE during
follow-up, seropositivity of anti-ganglioside M1, anti-ribosomal P and
anti-cardiolipin antibodies was found in 83.3%, 50% and 16.7%,
respectively of those patients, meaning that anti-ganglioside M1 had a
higher predictive value for NPSLE than other antibodies used in routine
laboratory diagnosis of NPSLE. Interestingly, all those patients were
seropositive for at least one of the studied antibodies. In contrast, none
of the 18 patients without clinical evidence of NPSLE was seropositive
for either anti-ganglioside M1 or anti-ribosomal P antibodies. Other
researchers reported a strong correlation between anti-ganglioside IgM
antibodies and neuropsychiatric manifestations. In contrast, they did
not ﬁnd a signiﬁcant correlation between anti-cardiolipin IgM and IgG
antibodies and neuropsychiatric manifestations (Costallat et al., 1990).
These investigators concluded that the analysis of anti-ganglioside IgM
antibodies showed an important predictive role for neuropsychiatric
manifestations in SLE and the negative test decreases the chance of the
neuropsychiatric manifestations.Thus, our ﬁndings indicate that serum anti-ganglioside M1
antibodies may be valuable predictors for NPSLE and when these
antibodies were measured with anti-ribosomal P antibodies, the
prediction value of both antibodies for NPSLE was 100%. Further
studies, on a large scale, regarding the predictive value of serum anti-
ganglioside M1 antibodies for NPSLE are warranted.
Cognitive dysfunction is one of the most frequent manifestations of
NPSLE that have a signiﬁcant impact on their ability to function (Sibbitt
et al., 2002). In the present study, clinical evidence of cognitive
dysfunction was found in 33.3% of all lupus patients and in 83.3% of
lupus with clinical evidence of NPSLE during follow-up. A recent study
conducted on a group of Egyptian children and adolescents with SLE
reported cognitive dysfunction in 68.2% (15/22) of patients with clinical
evidence of NPSLE (Mostafa et al., 2009).
There was a consistent ﬁnding in this study that deﬁcits were
found on only four subtests of the verbal and performance IQ (digit
span, arithmetic, digit symbol and block design). These tests are used
in a clinical setting to show abilities in workingmemory and attention
(digit span and arithmetic), processing speed (digit symbol) and
perceptual reasoning (block design). Thus, NPSLE may result in the
lack of attention and concentration, both of which may result in poor
scholastic achievement. We could not trace data in literature
regarding which subtests of verbal and performance IQ show deﬁcits
in lupus children to compare our results.
The key to establish an immunopathogenic role for a brain
autoantibody is to determine its effects on speciﬁc brain functions
(Greenwood et al., 2002). Thus, this study was the ﬁrst to investigate
the relationship between seropositivity of anti-ganglioside antibodies
and cognitive function. There was a signiﬁcant positive association
between anti-gangliosideM1 seropositivity and cognitive dysfunction
as the frequency of seropositivity of these antibodies was signiﬁcantly
higher in patients with cognitive dysfunction than patients with
normal cognitive function (Pb0.001). In addition, seropositivity of
anti-ganglioside M1 antibodies had a signiﬁcant risk for association
with cognitive dysfunction (odds ratio=36; 95% CI=4.3–302.8).
Thus, the relationship between anti-ganglioside M1 antibodies and
cognitive dysfunction may be a causal one in which these antibodies
might be playing a role in the pathogenesis of brain damage with
subsequent cognitive dysfunction. Little is known about the mechan-
isms and relevance of cognitive dysfunction in lupus patients who
never displayed major neuropsychiatric manifestations (Olazarán
et al., 2009). Some investigators demonstrated that cognitive
dysfunction in SLE reﬂects an immune-mediated compromise of an
underlying neural substrate rather than the non-speciﬁc effects of
disease activity, chronic illness or its treatment (Carbotte et al., 1995).
Whenever a lupus patient develops central or peripheral nervous
system manifestations, evaluation for systemic disease activity is
important to determine if the activation of the systemic disease is also
occurring (Navarrete and Brey, 2000). In the present study, there was
a non-signiﬁcant relationship between disease activity assessed by
SLEDAI and both clinical evidence of NPSLE and seropositivity of the
studied antibodies. NPSLE may occur as an isolated event without
other systemic signs of disease activity (Carbotte et al., 1995).
In addition, there was a non-signiﬁcant association between
seropositivity of both ANA and anti ds-DNA and clinical evidence of
NPSLE. Similarly, ANA and anti ds-DNA had no signiﬁcant association
with seropositivity of the studied antibodies, meaning that serum
ANA and anti ds-DNA are not reliable immumoserological markers of
diagnosis of NPSLE. A previous study also demonstrated the absence
of signiﬁcant associations between anti-ganglioside M1 antibodies
and ANA, anti ds-DNA and anti-cardiolipin antibodies (Galaezzi et al.,
2000).
In conclusion, serum anti-ganglioside M1 antibodies have a higher
predictive value for NPSLE than other antibodies used in routine
laboratory diagnosis of this disease. Thus, these antibodies may be
reliable parameters for the prediction of NPSLE, before clinical
201G.A. Mostafa et al. / Journal of Neuroimmunology 227 (2010) 195–201manifestations ensue, especially when they are measured with anti-
ribosomal P antibodies that are used in routine laboratory diagnosis of
NPSLE. In addition, anti-ganglioside M1 antibodies may play a role in
cognitive dysfunction that is found in some lupus patients. Further
studies, on a large scale, are warranted to evaluate the predictive
value of these antibodies in NPSLE. If this could be proved, this may
highlight the value of adding these parameters to the routine list of
investigations of SLE for early diagnosis and management of NPSLE
before the development of a debilitating disease.
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